FASN and lung carcinoma: Targeting FASN with C75 in mice leads to pronounced appetite suppression and weight loss, whereas EGCG, due to its lack of significant impact on CPT-1 activity, often does not cause weight loss while inhibiting the growth of adenocarcinoma- and lung carcinoma-derived xenografts [172].